<DOC>
	<DOCNO>NCT02308891</DOCNO>
	<brief_summary>Postendoscopic retrograde cholangiopancreatography pancreatitis frequent serious complication ERCP procedure , occur approximately 5-15 % unselected patient . Pharmacologic prevention post-ERCP pancreatitis topic several investigation recent year . Hydration consider mainstay treatment acute pancreatitis . We perform multicenter , prospective , randomized trial investigate whether intravenous vigorous hydration lactate Ringer 's solution reduces risk post-ERCP pancreatitis . Inclusion criterion : consecutive patient older 18 year schedule undergo diagnostic therapeutic ERCP recruit . Patients randomly assign 1:1 ratio receive either vigorous hydration ( treatment arm ) standard hydration ( standard arm ) . Randomization perform double blind fashion use computer-generated random number . Treatment arm ( vigorous hydration arm ) ; - Initial bolus lactate Ringer 's solution 10 mL/kg 1 hour prior ERCP - Intravenous lactate Ringer 's solution rate 3 mL/kg/h procedure continue 8 hour . - At end ERCP , post-procedure bolus lactate Ringer 's solution 10 mL/Kg 1hour Standard arm ( standard hydration arm ) ; - Patients receive lactate Ringer 's solution start ERCP fluid administer rate 1.5 ml/kg/h procedure 8hours ERCP . The primary endpoint development post-ERCP pancreatitis , define increase pancreatic pain ( 3 visual analogue pain scale ) hyperamylasemia ( three time upper limit normal ) . The secondary endpoint include development asymptomatic hyperamylasemia , severity pancreatitis , fluid overload .</brief_summary>
	<brief_title>A Prospective Trial Aggressive Hydration Strategy Reduce Post-ERCP Pancreatitis</brief_title>
	<detailed_description>Postendoscopic retrograde cholangiopancreatography pancreatitis frequent serious complication ERCP procedure , occur approximately 5-15 % unselected patient . Pharmacologic prevention post-ERCP pancreatitis topic several investigation recent year . Hydration consider mainstay treatment acute pancreatitis . We perform multicenter , prospective , randomized trial investigate whether intravenous vigorous hydration lactate Ringer 's solution reduces risk post-ERCP pancreatitis . Patients randomly assign 1:1 ratio receive either vigorous hydration ( treatment arm ) standard hydration ( standard arm ) . Randomization perform double blind fashion use computer-generated random number . Treatment arm ( vigorous hydration arm ) ; - Initial bolus lactate Ringer 's solution 10 mL/kg 1 hour prior ERCP - Intravenous lactate Ringer 's solution rate 3 mL/kg/h procedure continue 8 hour . - At end ERCP , post-procedure bolus lactate Ringer 's solution 10 mL/Kg 1 hour Standard arm ( standard hydration arm ) ; - Patients receive lactate Ringer 's solution start ERCP fluid administer rate 1.5 ml/kg/h procedure 8hours ERCP . The primary endpoint development post-ERCP pancreatitis , define increase pancreatic pain ( 3 visual analogue pain scale ) hyperamylasemia ( three time upper limit normal ) . The secondary endpoint include development asymptomatic hyperamylasemia , severity pancreatitis , fluid overload . Serum amylase level measure baseline , 8 hour 18-24 hour , 48 hour procedure . Investigators record detail maneuver perform , include : 1. total time procedure , 2. number attempt cannulation , 3. number pancreatic duct cannulation , 4. final diagnosis ERCP , 5. whether sphincterotomy , needle-knife papillotomy , stent placement 6. endoscopic papillary balloon dilation , 7. common bile duct ( C ) tissue sample ( biopsy , brush , cytology ) , 8. common bile duct-intraductal ultrasonography ( C-IDUS ) , - Serum amylase determine 8 , 18~24 , 48 hour ERCP . - If 12-hours serum amylase level &gt; 3 time upper normal limit patient exhibit pain nausea vomiting , patient pancreatitis . - Acute pancreatitis define serum amylase &gt; 3 time upper limit normal associate epigastric pain , back pain , epigastric tenderness . - Statistical analysis : 1 . Randomization do GI nurse , conceal envelop 2 . Data summarize descriptive statistic . 3 . The Chi square use compare categorical patient data . 4 . The Student 's test use compare continuous variable . 5 . Two-tailed P &lt; 0.05 consider indicate significance .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>consecutive patient older 18 year schedule undergo diagnostic therapeutic ERCP recruit Patients exclude acute pancreatitis 2 week ERCP , history chronic pancreatitis , previous sphincterotomy , refuse participate study protocol . Patients also exclude undergo ERCP , procedures stone removal follow previous sphincterotomy , change removal previous biliary stent , surveillance biopsy endoscopic papillectomy without pancreatography , consider carry minimal risk postERCP pancreatitis . Patients high risk fluid overload ( heart failure , NYHA II ; renal insufficiency , creatinine clearance &lt; 40ml/min ; liver cirrhosis ; hypoxemia , SaO2 &lt; 90 % ; sign pulmonary edema ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pancreatitis</keyword>
	<keyword>ERCP</keyword>
</DOC>